RSS Feed
- 5. Organization for Objective Review and Clinical Assessment March 2, 2026NAMCP has released an Organization for Objective Review and Clinical Assessment (OORCA) assessment for Acoramidis (Attruby™ marketed by BridgeBio), an oral, near-complete transthyretin stabilizer (≥ 90%), that is approved in the United States, Europe, and Japan for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. BridgeBio commissioned the National Association of Managed Care Physicians […]
- 3. Zanidatamab-hrii March 2, 2026Zanidatamab-hrii received Food and Drug Administration (FDA) approval for the treatment of adults with previously treated, unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry [IHC] 3+) biliary tract cancer (BTC), as detected by an FDA-approved test, on November 20, 2024. This indication is approved under accelerated approval based on overall response rate […]
- 4. Gilead Sciences, Inc. March 2, 2026Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US Food and Drug Administration (FDA) has approved YEZTUGO® (lenacapavir) injection, 463.5 mg/1.5 mL. Click here for full Prescribing Information, including BOXED WARNING. Click here to learn more at YeztugoHCP.com.
- 1. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance March 2, 2026Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
- 2. PAPZIMEOS March 2, 2026PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. PAPZIMEOS approval was supported by results from the pivotal Phase 1/2 study, which successfully met its primary safety and pre-specified primary eZicacy endpoints. Click here […]
- 8. LivaNova March 2, 2026LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
- Challenges in aligning IT infrastructure with value-based care goals and how to overcome them March 2, 2026Aligning IT with value-based care sounds like a tech roadmap problem, but it's really an operations problem: When you do value-based care right, it creates more work, not less. It demands proactive, team-based, person-centered care for whole panels of patients — on top of systems that were built for episodic visits and billing.
- How health systems are tackling behavioral health fragmentation March 2, 2026Health systems are responding to fragmented behavioral health care delivery in different ways: Expanding telepsychiatry in rural states, building pediatric health hubs that integrate mental and physical health on one campus, launching behavioral health urgent cares, and investing in navigators and data infrastructure to keep patients connected after discharge.
- Can the mental health benefits of exercise be bottled? March 2, 2026We all know the feeling: The mental clarity that comes after a good run or a heavy workout. Science backs this up, even showing that for non-severe depression, exercise can be just as effective as antidepressants or therapy. But there is a cruel irony at play: The symptoms of depression are often the very things […]
- Using saliva to detect disease holds promise, but it's not perfected yet March 2, 2026The saliva circulating in your mouth contains troves of microbial information about the rest of your body and is easier to collect than blood samples. Today, a few drops of spit can help detect viruses like HIV and the one that causes COVID-19, or assess genetic risks for breast cancer.
